ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Clinical trial NCT06664879 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06664879
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-30
- Primary completion
- 2028-07-31
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.